HDAC6-selective inhibitors are novel epigenetic anticancer agents. However, their precise mechanisms of action are incompletely understood. We investigated the anticancer mechanisms of the novel potent and selective HDAC6 inhibitor A452 compared with current clinically tested HDAC6 inhibitor ACY-1215. We demonstrate that A452 effectively inhibits the cell growth and viability of various cancer cell types, irrespective of p53 status. A452-induced apoptosis as evidenced by activated caspase 3 and PARP, increased Bak and Bax and decreased Bcl-xL. Moreover, A452 shifted cells away from antiapoptotic (AKT and ERK) pathways and toward proapoptotic (p38) pathways. A452 triggered DNA damage via increased γH2AX and activation of the checkpoint kinase Chk2. A452 induced the suppression of cell migration and invasion. Interestingly, A452 upregulated the expression of PD-L1, which regulates the PD-1 inhibitory pathway in T cells. Overall, our results suggest that A452 is more effective as an anticancer agent than ACY-1215. Therefore, therapeutically targeting HDAC6 may represent a novel strategy for cancer treatment irrespective of the p53 mutation status.
Introduction
Histone deacetylases (HDACs) were originally classified as histone modifiers but have more recently been found to target diverse other proteins involved in various cellular processes unrelated to the chromatin environment (1) . In this context, HDAC6 is considered to be among the most representative HDACs. HDAC6 is unique among HDACs in being a predominant cytoplasmic protein (2) by containing two deacetylase domains and a C-terminal zinc finger domain binding with high affinity to free ubiquitin as well as ubiquitinated proteins (3) . Unlike other HDACs, HDAC6 has a unique substrate specificity for nonhistone proteins, such as tubulin, heat shock protein 90, peroxidases and some DNA repair proteins (4) . Moreover, HDAC6 plays a key role in the cellular response to the accumulation of misfolded and aggregated proteins that are key regulators of neurological disorders, including Alzheimer's, Huntington's and Parkinson's disease. In addition to neurodegenerative disorders, HDAC6 can influence multiple cancer-linked cellular pathways, making it a pivotal therapeutic target for cancer treatment. The deregulation of HDAC6 is correlated with malignant progression in various cancers including human breast and ovarian cancers (5) .
The selective inhibition of HDAC6 exerts multiple anticancer effects by inducing cell differentiation, cell-cycle arrest, apoptosis, autophagy, susceptibility to chemotherapy, inhibition of migration and angiogenesis and improved tumor immunity (6, 7) . Interestingly, unlike other HDACs, the selective inhibition of HDAC6 is not believed to be associated with severe toxicity, and the HDAC6 knockout is not associated with embryonic lethality (8) . Due to this therapeutic advantage, an HDAC6-selctive inhibitor has emerged as an attractive new approach in the development of cancer therapeutics. Several HDAC6-selective inhibitors have been previously reported and tested as anticancer drugs (9-13); however, despite extensive efforts, ACY-1215 (rocilinostat) is currently exclusively being clinically tested for the treatment of only refractory multiple myeloma alone and in combination with other anticancer drugs but not for solid tumors (12) . To date, the clinical efficacy of all HDAC inhibitors (e.g. pan-HDAC and HDAC6-selective inhibitors), particularly in solid tumors, remains elusive (14) . Therefore, there is a need to develop novel HDAC6-selective inhibitors that are effective in solid tumors as well as hematological cancers.
p53 inactivation is a major driving force for tumorigenesis and tumor suppressor gene TP53 mutations are very common in human cancer (15) . Unlike most tumor suppressors, the majority of cancer-related TP53 mutations consists of missense mutations in the p53 DNA-binding domain, often yielding a stable, overexpressed mutant (mut) p53 protein (16) . Some of these mutants can lose both their tumor-suppressive functionality as well as permit cells with oncogenic gain-of-function activities (e.g. enhanced proliferation, invasion and migration, genomic instability and chemotherapy resistance). These gain-of-function properties contribute to tumor aggressiveness, high recurrence and poor prognosis (17) . Considering that more than 50% human tumors have TP53 mutations, there is a need to develop an anticancer agent that is effective in both wild-type (wt) p53 and mutp53 harboring tumors.
To shed further light on this issue, we investigated the extent to which the anticancer effects of HDAC6-selective inhibition are influenced by the p53 status using various cancer cells expressing different p53 mutations. In the present study, we report the anticancer mechanisms of N-hydroxy
which is a novel, potent, selective HDAC6 inhibitor, compared with current clinically studied HDAC6 inhibitor ACY-1215. A452 induces cell death and significant growth inhibition in a panel of cancer cells but not normal cells irrespective of p53 mutation status. Moreover, A452 markedly suppresses cancer-cell migration and invasion. Finally, at the molecular level, we present evidence that both the p53 and mitogen-activated protein kinases (MAPK) pathways are involved in the anticancer mechanisms of A452. Interestingly, A452 was found to upregulate PD-L1 expression. Collectively, these data suggest that the HDAC6-selective inhibitor presents a novel epigenetic anticancer agent that can be applied to both wtp53-bearing and mutp53-bearing cancers, with similar efficacy.
Materials and methods

Cell culture and drug treatment
The human colorectal cancer cell lines (HCT116, HT29, LoVo, SW480, SW620, HCT15, DLD1, Caco2) and normal cell line (FHC) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). p53 null HCT116 cell line was a generous gift from In-Chul Park (Korea Institute of Radiological & Medical Sciences, Seoul, Korea) (18, 19) . The cells were cultured in medium (HyClone) containing 10% fetal bovine serum, 100 units/ ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere of 5% CO 2 and 95% air at 37°C. Cell lines were authenticated and characterized by the supplier. ATCC uses morphology, karyotyping and PCR-based approaches to confirm the identity of cell lines. The cells were treated with DMSO, suberoylanilide hydroxamic acid (SAHA) (Sigma-Aldrich, St. Louis, MO), ACY-1215, cisplatin, capecitabine, tubastatin A, irinotecan (Selleck Chemicals) or A452 (a γ-lactam based HDAC6 inhibitor) (20) , which was kindly provided by Dr. Gyoonhee Han (Yonsei University, Seoul, Korea).
Small interfering RNA (siRNA) transfection
The following siRNAs were used: control luciferase siRNA and HDAC6 siRNA (Santa Cruz, sc-35544, Dallas, TX). For transfection, the cells were grown to 80% confluence and then transfected with siRNA (100 nM) using RNAiMAX Lipofectamine reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. A 96-well-plate format was used and the cells were incubated with the siRNA-RNAiMAX complex for 24 h. The medium was then replaced with fresh serum-free medium after 24 h.
Short hairpin RNA (shRNA) infection and the generation of stable knockdown cell lines
The lentiviral shRNA sets for HDAC6 were purchased from Sigma-Aldrich (St. Louis, MO). The following sequences within human HDAC6 were targeted: CCGGCATCCCATCCTGAATATCCTTCTCGAGAAGGATATTCAG GATGGGATGTTTTT (#1, NM_006044.2-3840s1c1 TRCN0000004839) and CCGGCGGTAATGGAACTCAGCACATCTCGAGATGTGCTGAGTTCCATT ACCGTTTTT (#2, NM_006044.2-2049s1c1, TRCN0000004842). To generate the respective lentivirus, HEK293T cells were cotransfected with the shRNA vector and necessary packaging plasmids. Supernatants containing lentivirus were collected 48 and 72 h after transfection and passed through a 0.45 μm filter. Subsequently, the cells were infected three times (every 12 h) with lentivirus in the presence of hexadimethrine bromide. The cells were selected for over 2 days in 2 μg/ml puromycin, as the pLKO.1 vector encodes the respective antibiotic-resistance gene.
Cell growth and viability assay
To monitor cell growth and viability, the cells were seeded in triplicate at a density of 3-6 × 10 3 cells in 200 μl of medium in 96-well plates. The drugs were added at the indicated concentrations 24 h after seeding. Following the drug treatment, 20 μl of a water-soluble tetrazolium salt, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H tetrazolium, monosodium salt (WST-8; CCK-8 kit, CK04, Dojindo Molecular Technologies, INC. Rockville, MD) reagent was added to the culture and the reaction mixtures were incubated at 37°C for 4 h. The absorbance readings for each well were carried out at 450 nm using a multimode microplate reader (Teckan, Maennedorf, Switzerland). The results are presented as the percent absorbance relative to the control cultures and were generated from three independent experiments performed in triplicate.
Growth-inhibitory and viability-inhibitory assays
The drug concentrations that inhibited 50% cell growth (GI 50 ) and 50% cell viability (IC 50 ) were determined using a CCK-8 assay as described elsewhere. All cell lines were treated for 72 h on day 2 unless otherwise stated. GI 50 and IC 50 were determined using Prism Version 6.0 software (GraphPad).
Proliferation assay
The effect of the HDAC6 knockdown on HCT116 and HT29 cell proliferation was monitored in real-time using the IncuCyte TM Live-Cell Imaging System (Essen BioScience, Hertfordshire, UK 
Western blot assay
Cells grown and treated as indicated were collected, lysed and separated by SDS-PAGE; western blotting was performed as previously described (21). The source of the primary antibodies is presented in the Supplementary Material and Method, available at Carcinogenesis Online.
Colony-formation assay
Soft agar assays were carried out in six-well plates in which 2 ml 1× RPMI1640 with 10% fetal bovine serum was overlaid with 1 ml of 0.5% base agar and 0.25% top agar in 1× RPMI1640 with 10% fetal bovine serum containing the cells. Cells of each clone (2 × 10 4 ) were plated. 0.5 ml volume of culture medium was added to the top of each plate every 5 days and the cells were grown at 37°C for 21 days. The plates were stained with 1 ml 0.05% crystal violet (Sigma, St. Louis, MO) for > 1 h and colonies were counted using a microscope and then quantified.
Transwell invasion assay
An in vitro transwell invasion assay was performed using a 24-well transwell unit (8 μm pore size) with polyvinylpyrrolidone-free polycarbonate filters. The filters were washed thoroughly in PBS and dried immediately before use. The cells were placed in the upper part of the transwell plate and incubated with A452 or HDAC6 siRNA for 48 h at 37°C. The cells that migrated to the lower surface of the membrane were fixed in methanol and stained with 0.5% crystal violet for 10 min. Finally, we determined the migratory phenotypes by counting the cells that migrated to the lower side of the filter using microscope at 200× magnification.
Wound healing assay
To determine cell motility, HCT116 and HT29 cells (5 × 10 5 cells per well) were seeded in 12-well tissue culture plates and grown to 80-90% confluence. After aspirating the medium, the centers of the cell monolayers were scraped with a sterile micropipette tip to create a denuded zone (gap) of a constant width. Subsequently, cellular debris was washed with PBS, and the HCT116 and HT29 cells were exposed to A452 (2 μM). The wound closure was monitored and photographed at 0, 24 and 48 h. To quantify the number of migrated cells, pictures of the initial wounded monolayers were compared with corresponding pictures of cells at the end of incubation. Artificial lines fitting the cut edges were drawn on pictures of the original wounds and overlaid onto the pictures of the cultures after incubation. The cells that migrated across the lines were counted in six random fields from each triplicate treatment, and the data are presented as the mean ± SD.
Annexin V/propidium iodide (PI) assay and flow cytometry
Apoptosis was assessed using Annexin V-PI double staining according to the manufacturer's instructions (FITC Annexin V Apoptosis Detection Kit; BD Pharmingen, San Jose, CA). Following treatment, the cells were trypsinized and stained with 0.5 mg/ml Annexin V in binding buffer (10 mM HEPES free acid, 0.14 M NaCl and 2.5 mM CaCl 2 ) for 45 min. Afterward, PI (5 mg/ml final concentration) was added and incubated for another 15 min. The stained cells were then subjected to flow cytometry for phenotypic analysis of the number of apoptotic cells.
Caspase-3 activity assay
The level of caspase-3 activity was assayed using a Caspase-3 Colorimetric Assay kit (Biovision, Palo Alto, CA). A total of 3 × 10 6 cancer cells treated with or without the extracts at 37°C, 5% CO 2 for 24 h were pelleted via centrifugation and resuspended with lysis buffer. The cell lysates were then incubated on ice for 10 min before centrifugation (15 000 rpm, 1 min). A reaction buffer containing 10 mM dithiothreitol was added to the supernatants of each cell lysate and incubated for 30 min on ice. The control was prepared by adding 1 μl of 1 mM Z-VAD-fmk (pan-caspase inhibitor) to the cell samples treated with the extracts. A volume of 5 μl of caspase-3 substrate (Ac-DEVD-pNA) was added to all tubes and incubated at 37°C for 1 h. The enzyme-catalyzed release of the p-nitroanilide product was measured at 405 nm using a multimode microplate reader (Teckan, Maennedorf, Switzerland).
Statistical analysis
All data are presented as the mean ± SD from three independent experiments. Statistical significance was determined by Student's t-test of the treated samples compared to the respective control, *P < 0.05; **P < 0.01; ***P < 0.001.
Results
A452 selectively inhibits HDAC6
A452 is a hydroxamic acid-based, small-molecule inhibitor with a γ-lactam core that selectively inhibits HDAC6 catalytic activity ( Figure 1A ). We previously reported that A452 has an IC 50 of 0.8 nM for HDAC6 compared with 25.6 nM for HDAC1 using an in vitro HDAC inhibition assay (20) and was found to be 32-fold less active against HDAC1. To determine whether A452 is a selective inhibitor of HDAC6 in a cancer-cell panel, we assayed its ability to inhibit class I HDACs compared with HDAC6. Although A452 had differential effects in the various cancer cell lines, A452 showed good HDAC6-inhibitory activity as evidenced by increased levels of acetylated α-tubulin, an HDAC6 substrate ( Supplementary Figures 1 and 2 , available at Carcinogenesis Online). Among the cancer cells, we focused on human colorectal cancer (CRC), which showed differential HDAC6-inhibitory effects by A452 ( Figure 1B) ; high HDAC6 expression and high rates of relapse, metastasis and mortality. In CRC HCT116 and HT29 cells, a dose-dependent increase in acetylated α-tubulin was observed at low doses (10 nM) of A452 without affecting histone acetylation, confirming the selective inhibition of HDAC6 activity in vivo ( Figure 1C and D) . However, higher exposures led to inhibition of class I HDACs. Treatment with the only clinically tested HDAC6 inhibitor, ACY-1215, similarly increased acetylation of α-tubulin and histone H3 in CRC cells (Supplementary Figure 4A and B, available at Carcinogenesis Online). These results demonstrate that A452 is a selective and potent HDAC6 inhibitor.
A452 inhibits cell growth and viability of transformed but not normal cells
We examined the effect of A452 on cell growth and viability of HCT116 and HT29 CRC cells. The cells were cultured with A452 for up to 72 h and cell growth and viability were measured using a CCK-8 assays. A452 treatment resulted in a significant time-dependent and dose-dependent inhibition of cell growth and viability (Figure 2A-F) . The cells were cultured with A452, conventional chemotherapeutic drugs, the topoisomerase I inhibitor irinotecan, the DNA synthesis inhibitor capecitabine (a 5-fluorouracil prodrug), the DNA-damaging agent cisplatin or the pan-HDACi SAHA (suberoylanilide hydroxamic acid) for up to 72 h. A452-induced cell death was markedly higher than that induced by the other chemotherapeutics at 72 h. (A452 2 μM; 88 versus 72%, cisplatin; 17 versus 13%, irinotecan; 48 versus 36%, capecitabine; and 65 versus 48% in HCT116 and HT29 cells, respectively; Figure 2G and H). These results were confirmed with long-term clonogenic assays ( Figure 2I ). Next, we determined the effect of A452 on the cell growth and viability of normal fetal colon epithelial cells (FHCs), foreskin fibroblasts (BJ), human dermal fibroblasts (HDF) and 23 other transformed cancer-cell lines, including those derived from eight different histological types of solid tumors, cultured with A452 for up to 72 h. A452 inhibited the growth and decreased the cell viability of transformed but not normal cells in a concentration-dependent manner (Table 1 and Supplementary  Figure 3 , available at Carcinogenesis Online). In addition, A452 induced cytotoxicity in both wtp53-bearing and mutp53-bearing cancers, with a similar efficacy. In both normal and transformed cells, A452 induced acetylated accumulation of α-tubulin (Supplementary Figures 1-3 , available at Carcinogenesis Online). Similar to A452 treatment, an HDAC6 knockdown with short hairpin RNA (shRNA) decreased the cell growth rate and cell viability (Figure 2J and K; Supplementary Figure 5A and B, available at Carcinogenesis Online) of the CRC cells. Furthermore, the growth (13-14-fold) and viability inhibitory effect (5-7-fold) of The effect of the HDAC6 knockdown on HCT116 (J) and HT29 (K) cell proliferation. Cell proliferation was monitored for 10 days (240 h) using an IncuCyte ZOOM system in an incubator (5% CO 2 , at 37°C). Cell proliferation in the cells in which HDAC6 was downregulated was decreased to a comparable degree of A452. Data are expressed as the mean ± SD from three independent experiments (n = 3). *P < 0.05, **P < 0.01 or ***P < 0.001 versus the DMSO control, Student's t-test. Figure 4C , available at Carcinogenesis Online). Taken together, these findings show that HDAC6-selective inhibition by A452 induces cell death in various transformed but not normal cells irrespective of the p53 mutation status.
A452 was greater than for ACY-1215 in CRC cells (Supplementary
A452 induces caspase-dependent and differentially coordinated p53-induced apoptosis
Similar to other antineoplastic agents, HDAC inhibitors should trigger cell death through apoptosis induction (22) . To investigate the mechanism of cell death in CRC cells cultured with A452, we evaluated the effect of A452 on apoptosis-related proteins, caspase activity and propidium iodide (PI) uptake analyses. In both HCT116 and HT29 cells cultured with A452, the level of fulllength poly (ADP ribose) polymerase (PARP) decreased, with a concomitant increase in PARP cleaved by caspase-3 as a marker of apoptosis (23) in a dose-dependent manner ( Figure 3A and B) . Next, we assessed the potential changes in known proapoptotic (Bax and Bak) and antiapoptotic (Bcl-xL) molecules. Increased Bak and Bax levels and decreased Bcl-xL expression was induced by A452 treatment compared to the controls. In contrast, PARP and caspase-3 levels and Bak-to-Bcl-xL ratio remained unchanged following treatment with ACY-1215, suggesting that ACY-1215 alone does not efficiently induce apoptosis in CRC (Supplementary Figure 6A , available at Carcinogenesis Online). Similar to A452 treatment, the HDAC6 knockdown effectively induced apoptosis through caspase-3 (cleaved PARP) activation and an increase in the Bak-to-Bcl-xL ratio (Supplementary Figure 5C and D, available at Carcinogenesis Online). To further confirm this result, we tested the effect of A452 on apoptosis induction in diverse colon cancer-cell lines possessing different mutant levels of p53. Similar results were also observed in other colon cancer cells (Supplementary Figure 7 , available at Carcinogenesis Online). Our previous studies demonstrated that HDAC6 deacetylates p53 at lysines 381/382 (Lys381/382) and modulates its stability and activity (24) . Indeed, A452 treatment differently modulated p53 by upregulating wtp53 and downregulating mutp53, resulting in differentially coordinated p53-induced apoptosis in various CRC cells (Figure 4 ; Supplementary Figure 7 and Table 1 , available at Carcinogenesis Online). However, the effects of ACY-1215 on expression levels and stability of p53 were not observed in both CRC cells (Supplementary Figure 6B , available at Carcinogenesis Online). Both A452 and SAHA induced a dramatic increase in caspase-3 activity in CRC cells compared to other chemotherapeutic drugs, as determined by flow cytometry (Figure 3C and D) . Consistently, Annexin V/PI staining revealed significantly increased cell apoptosis upon A452 treatment ( Figure 3E and F) . Overall, our results suggest that A452-induced cell death is at least partially dependent on caspase activation and p53 pathway irrespective of the p53 mutation status.
A452 induces γH2AX accumulation and Chk2 activation
The HDAC6-selective inhibitor tubacin and the pan-HDAC inhibitor SAHA promotes the accumulation of phosphorylated histone H2AX (γH2AX), an early indicator of DNA double-strand breaks, as well as the activation of the checkpoint kinase (Chk2), which is phosphorylated in response to DNA damage (25) . Thus, we tested whether A452 activates a DNA damage response. A452 increased γH2AX accumulation and Chk2 phosphorylation levels in the CRC cells ( Figure 3A and B) . Similar results were observed following an HDAC6 shRNA knockdown in both CRC cell lines (Supplementary Figure 5C and D, available at Carcinogenesis Online). However, ACY-1215 left DNA damage response unaffected (Supplementary Figure 8 , available at Carcinogenesis Online). These data suggest that an HDAC6-selective inhibition by A452 causes DNA damage in CRC cells. were treated with the indicated compounds for 48 h and stained with annexin V and PI for 45 min. Apoptosis induced by these compounds was then assessed by flow cytometry (n = 3). Data are expressed as mean ± SD from three independent experiments. *P < 0.05 or **P < 0.01 versus the DMSO control, Student's t-test.
Inhibition of AKT and ERK and the activation of p38 contribute to A452-induced apoptosis
Multiple reports have demonstrated that the phosphatidylinositol-3-kinase (PI3K)/Akt and MAPK, including the extracellular signal-regulated kinase (ERK) and p38 pathways play key roles in cancer-cell invasion and metastasis as well as cell proliferation, differentiation and survival (26) . We examined whether A452 alters the phosphorylation levels of MAP kinase members and Akt. Consistent with the increased apoptosis (Figure 3 ), A452 decreased the phosphorylation level of AKT and total AKT. Moreover, A452 markedly increased p38 MAPK phosphorylation, accompanied by ERK1/2 dephosphorylation without changes in the total ERK1/2 in both of the tested cells (Figure 4 ). Similar to A452 treatment, ACY-1215 showed similar effects, suggesting that this effect is due to HDAC6 inhibition (Supplementary Figure 6C , available at Carcinogenesis Online). Together, these findings indicate that A452 leads to a shift away from the antiapoptotic (e.g. AKT and ERK) and toward the proapoptotic (e.g. p38) pathways.
A452 suppresses cellular migration and invasion
Next, we investigated the role of HDAC6 in the migration and invasion of CRC cells. HDAC6 inhibition by A452 or an HDAC6 small interfering RNA (siRNA) knockdown suppressed cellular migration and invasion compared to the controls in both the wound healing assay (Figure 5A and B; Supplementary Figures 9 and 10, available at Carcinogenesis Online) and the transwell migration test (Figure 5C and D) . We also assessed the metastatic ability using immunoblotting. As shown in Figure 5E and F, HDAC6 inhibition by A452 or the HDAC6 siRNA knockdown could influence CRC cell metastasis by regulating matrix metalloproteinase 2 (MMP2), MMP9 and vimentin, which are markers of cancer-cell metastatic ability. In contrast, ACY-1215 did not largely influence CRC cell metastasis ( Supplementary Figures 11  and 12 , available at Carcinogenesis Online). These findings suggest that an HDAC6-selective inhibition by A452 inhibits CRC metastasis.
Selective inhibition of HDAC6 controls PD-L1 upregulation in CRC cells
A recent report demonstrated that pan-HDAC inhibitors and class I HDAC inhibitors upregulate programmed death-ligand 1 (PD-L1) expression via STAT3 pathway, while HDAC6 and HDAC8 inhibitors do not alter the level of PD-L1 expression in melanomas (27) . Thus, we determined whether the effect of HDAC6 on PD-L1 expression could be recapitulated in CRC cells. An 
Discussion
HDAC6 is known to regulate the function of histones and non-histone proteins through the acetylation of specific sites. Immunoblotting analysis was performed with the indicated antibodies. β-actin is used as a loading control.
Moreover, HDAC6 should be considered a novel epigenetic target for cancer therapy as a result of its key role in many biological processes that regulate malignant cells regarding the survival and maintenance of the malignant phenotype (4). Although there are currently no HDAC6-targeting agents approved for clinical use, preclinical and some emerging clinical studies have shown promising results with HDAC6 inhibitors as anticancer agents in various cancers. The HDAC6 selective inhibitor, ACY-1215, alone or in combination with bortezomib was reported to inhibit multiple myeloma cell growth (12) ; however, the effect of ACY-1215 on solid tumors was not evaluated. In this study, we report the anticancer mechanisms of action of a novel HDAC6-selective inhibitor, A452, in solid tumors, particularly colon cancer, compared with current clinically tested HDAC6 inhibitor ACY-1215. We demonstrate that the genetic knockdown and pharmacological inhibition of HDAC6 impairs cancer cell growth and viability, induce apoptosis and DNA damage, suppresses migration and invasion and influences immune-related pathways in CRC cells. Since over 50% of human tumors have TP53 mutations, therapeutic strategies that do not rely on functional p53 have long conceived clinically more preferable. However, because the mutp53 protein is still retained and accumulates in tumors, destabilizing or reactivating the function of mutp53 is a promising anticancer strategy. In addition, because the TP53 gene often remains the wild-type in murine double minute (MDM)-2 or MDMX-overexpressing cancers, restoring of wtp53 activity by counteracting p53 repressors (MDM2 and MDMX) is another attractive anticancer strategy (28) (29) (30) . The development of small molecules targeting p53 is a rapidly evolving area of cancer treatment. Many compounds are currently in preclinical testing and several are already in clinical trials (31) . Although MDM2 inhibitors (e.g. nutlin-3a) that disrupt the MDM2-p53 interaction can inhibit tumor growth and are currently undergoing clinical testing, they are less effective in cancer cells that express high levels of MDMX (32) . We have recently reported that HDAC6 deacetylates p53 at Lys381/382 and controls p53 stability and activity, resulting in differentially coordinated p53-induced apoptosis (24) . In this study, we further validated that HDAC6 inhibition by A452 or an HDAC6 knockdown by siRNA leads to cell death via the reduction of hyperstable mutp53 as an oncogene in mutp53 cancer cells and by wtp53 reactivation as a tumor suppressor in wtp53 cancer cells. Our data indicate that A452 exerts anticancer effects via p53. In contrast, the expression levels and stability of p53 remain unchanged following treatment with ACY-1215 irrespective of the p53 status. Hence, A452 and ACY-1215 can exert distinct effects on p53 expression and stability and p53-induced apoptosis in CRC cells. Overall, these data suggest that HDAC6 might be a key regulator that differentially modulates p53 stability and function dependent on the p53 mutation status. In this regard, the HDAC6-selective inhibitor, A452, might be a promising anticancer agent that is effective against both wtp53 and mutp53 harboring tumors.
PD-1 expressing T cells can interact with tumors expressing PD-1 ligands, leading to immunological tolerance in the tumor microenvironment (33, 34) . Therapies that target this immune checkpoint system have proven clinically successful for the treatment of non-small cell lung cancer (35) , metastatic melanoma (36) (37) (38) (39) and other malignancies (40) . Beyond direct tumor cell cytotoxicity, HDAC inhibitors can also change the immunogenicity and augment antitumor immune responses (1, 41) . In addition, HDAC inhibitors can decrease negative cell populations (e.g. myeloid-derived suppressor cells) and augment checkpoint blockade therapies (e.g. PD-1 antibodies) (42) . Recently, interesting results have reported that pan-HDAC inhibitors (LBH589 and PDX101) and class I HDAC inhibitors (MS-275 and MGCD0103) upregulate PD-L1 and, to a lesser extent, PD-L2 in melanoma, while HDAC6 inhibitors (ACY-1215 and nexturastat) and HDAC8 inhibitor (PCI34051) did not alter PD-L1 expression (27) . HDAC inhibitor treatment caused the increased levels of histone acetylation of the PD-L1 gene resulting in augmented and prolonged gene expression. In contrast, Lienlaf et al. (43) reported that the pharmacological or genetic inhibition of HDAC6 downregulates PD-L1 expression via the STAT3 pathway in melanoma. Contrary to this finding, our data showed that HDAC6 inhibition via A452 or ACY-1215 or silencing of HDAC6 upregulated PD-L1 via STAT3 activation in CRC cells. In addition to monotherapy, a combination treatment of a pan-HDAC inhibitor with a PD-1 blockade results in a slower melanoma progression and increased survival compared with control and single-agent treatments (27) . Importantly, the tumor expression of PD-L1 appears to be correlated with the response to PD-1 blocking antibodies (44) and may emerge as a clinically relevant biomarker. Recent clinical trials involving immune checkpoint blockade have led to the initiation of a clinical trial combining anti-PD-1 antibody (nivolumab), 5-azacytidine (DNA methyltransferase inhibitor) and MS-275/etinostat (class I HDAC inhibitor) in NSCLC patients (https://clinicaltrials.gov). Overall, these data demonstrate the ability of HDAC inhibitors to enhance immunotherapies and provide a rationale for combining such HDAC inhibitors with a PD-1 blockade. To date, there is no evidence supporting that the combination of a HDAC inhibitor and PD-L1 blockade exerts antitumor effects. Thus, further study is needed to investigate the effect of PD-L1 blocking antibodies on the tumoral expression of PD-L1. Furthermore, future researches are required to clarify whether the selective inhibition of HDAC6 controls PD-L1 expression in a cell type-specific manner and if HDAC6-selective inhibitors function as potential immunomodulatory agents in cancer.
In conclusion, our study is the first systemic comparison that includes a random selection of established human null p53, wtp53 and mutp53 tumor cells, and clearly demonstrates a significantly increased responsiveness in wtp53 and mutp53 tumors via the differential modulation of p53 by an HDAC6-selective inhibitor A452 but not ACY-1215. A452 effectively provokes CRC cell apoptosis through caspase-3 activation and elevation of the Bax-to-Bcl-xL ratio. In addition, the increase of phospho-p38 as well as a predominant decline of phospho-ERK and phospho-AKT was present in A452-treated CRC cells. Furthermore, A452 inhibits cellular migration and invasion. Finally, A452 controls STAT3 phosphorylation and PD-L1 expression in CRC cells. In this study, we provide novel in vitro mechanistic data to complement our previous in vivo data revealing that mice carrying an HCT116 tumor xenograft displayed decreased tumor growth following A452 treatment without fluctuations in body weight (20) . In contrast, ACY-1215, which is the only firstin-class clinically relevant HDAC6-selctive inhibitor for hematological cancers, modestly reduces cell proliferation and does not induce efficiently apoptosis in CRC cells. ACY-1215 may be not potent enough as a monotherapy to treat solid tumors including CRC. By making comparisons with ACY-1215, we show that A452 is a mechanistically novel agent with the mechanism of action of HDAC6 selective inhibitor. Taken together, these findings suggest that HDAC6-selective inhibition by A452 is a novel epigenetic anticancer therapeutic strategy that can be applied to both wtp53-bearing and mutp53-bearing cancers, with similar efficacy. These interesting results provide a rationale for the future clinical development of HDAC6 selective inhibitors to treat patients with solid tumors.
